Eroxon was first studied in a randomized, double-masked, placebo-controlled, home-use, parallel-group clinical trial. Subjects first had to try regular sexual activity over four weeks on at least four occasions to establish the severity of their ED. This provided a pre-treatment baseline.
The Phase 3 study was designed to investigate the efficacy and safety of Eroxon gel in mild, moderate and severe ED patients. In the study, Eroxon consistently showed statistical improvement over the pre-treatment baseline and achieved clinically significant differences across all ED severities. Eroxon also showed efficacy and a rapid speed of onset with an excellent safety profile.